Erratum: Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia (British Journal of Cancer (2006) 95, (401-405) DOI: 10.1038/sj.bjc.6603246);Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia

British Journal of Cancer

Volumn 95, Issue 3, 2006, Pages 401-405

  Pashayan, N ^a   Powles, J ^a   Brown, C ^b   Duffy, S W ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Eastern Cancer Registration and Information Centre   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Excess cases; Overdiagnosis; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; UNITED KINGDOM;

EID: 33746913850     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603330     Document Type: Erratum

References (17)

1. Auvinen A, Maattanen L, Stenman UH, Tamela T, Ranniko S, Aro J, Juusela H, Hakama M (2002) Lead-time in prostate cancer screening (Finland). Cancer Causes Control 13(3): 279-285
2. Ciatto S, Gervasi G, Bonardi R, Frullini P, Zendron P, Lombardi C, Crocetti E, Zappa M (2005) Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer 41(3): 411-415
3. Draisma G, Boer R, Otto SJ, van der Gruijsen IW, Damhuis RA, Schroden FH, de Koning HJ (2003) Lead times and overdetection due to prostate - specific antigen screening estimates from the European Randomized Study of Screening for prostate cancer. J Natl cancer Inst 95(12): 868-878
4. Duffy SW, Hill C, Esteve J (eds) (2001) Quantitative Methods for the Evaluation of Cancer Screening. Arnold: London
5. -1: a randomized study of 6 vs 12 core transperineal prostate biopsy. J Urol 171: 197-199
6. Etzioni R, Person DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Can Inst 94(13): 981-989
7. Gann PH, Hennekens CH, Stampfer MJ (1995) A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273(4): 289-294
8. Hugosson J, Aus G, Becker C, Carlsson S, Eriksson H, Lilja H, Lodding P, Tibblin G (2000) Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int 85(9): 1078-1084
9. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG (2004) Results of randomised, population- based study of biennial screening using serum prostate-specific antigen measurement to detect prostate cancer. Cancer 100: 1397-1405
10. McGregor M, Hanley JA, Boivin JF, McLean RG (1998) Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159(11): 1368-1372
11. Melia J, Moss M (2001) Survey of the rate of PSA testing in general practice. BJOC 85(5): 656-657
12. Paci E, Warwick J, Falini P, Duffy SW (2004) Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen 11: 23-27
13. Pashayan N, Powles J, Brown C, Duffy SW (2006) Incidence trends of prostate cancer in East Anglia, before and after the era of PSA diagnostic testing. Br J Cancer 95: 398-400
14. Perrin P, Maquet JH, Bringeon G, Devonec M (1991) Screening for prostate cancer. Comparison of transrectal ultrasound, prostate specific antigen and rectal examination. Br J Urol 68: 263-265
15. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D (1997) Diagnosis, management and screening of early localised prostate cancer. HTA 1(2): 1-96
16. Smith DS, Catalona WJ (1994) The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152: 1732-1736
17. Tornblom M, Eriksson H, Franzen S, Gustafsson O, Lilia H, Norming U, Hugosson J (2004) Lead time associated with screening for prostate cancer. Int J Cancer 108(1): 122-129